Patents Assigned to ImClone Systems Incorporated
-
Publication number: 20090306348Abstract: The present invention provides formulations and methods for the stabilization of antibodies. In one embodiment, the invention provides the stabile formulation of antibodies that are prone to non-enzymatic fragmentation at the hinge region. In a further embodiment, the invention provides methods of stabilization of antibodies comprising lyophilizing an aqueous formulation of an antibody. The formulations can be lyophilized to stabilize the antibodies during processing and storage, and then the formulations can be reconstituted for pharmaceutical administration. In one embodiment, the present invention provides methods of stabilization of anti-VEGFR antibodies comprising lyophilizing an aqueous formulation of an anti-VEGFR antibody. The formulations can be lyophilized to stabilize the anti-VEGFR antibodies during processing and storage, and then the formulations can be reconstituted for pharmaceutical administration.Type: ApplicationFiled: February 15, 2007Publication date: December 10, 2009Applicant: ImClone Systems IncorporatedInventors: Joel Goldstein, Arvind Srivastava
-
Publication number: 20090297509Abstract: A method to inhibit the growth of tumors in human patients, comprising treating the human patients with an effective amount of a combination of radiation and a non-radiolabeled protein receptor tyrosine kinase inhibitor, the overexpression of which can lead to tumorigenesis.Type: ApplicationFiled: January 26, 2009Publication date: December 3, 2009Applicant: ImClone Systems IncorporatedInventors: Harlan W. Waksal, Mansoor N. Saleh, Francisco Robert, Donald Jay Buchsbaum
-
Publication number: 20090142358Abstract: The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal.Type: ApplicationFiled: September 19, 2008Publication date: June 4, 2009Applicant: ImClone Systems IncorporatedInventor: Zhenping Zhu
-
Publication number: 20090136510Abstract: The invention provides antibodies or fragments thereof, including human antibodies, specific for Macrophage-Stimulating Protein Receptor (MSP-R or RON), which inhibit RON activation. Also provided are methods to inhibit RON, particularly the use of RON antibodies to treat diseases such as cancer.Type: ApplicationFiled: November 21, 2008Publication date: May 28, 2009Applicant: ImClone Systems IncorporatedInventors: Daniel Pereira, Jennifer O'Toole
-
Publication number: 20090110678Abstract: The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFR? antagonist. The invention also provides antibodies that bind to human PDGFR? and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFR?, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents.Type: ApplicationFiled: June 19, 2006Publication date: April 30, 2009Applicants: ImClone Systems Incorporated, University of WashingtonInventors: Dale L. Ludwig, Stephen R. Plymate
-
Publication number: 20090099339Abstract: Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.Type: ApplicationFiled: July 9, 2008Publication date: April 16, 2009Applicant: ImClone Systems IncorporatedInventors: Neil I. Goldstein, Nicholas A. Giorgio, Steven Tarran Jones, Jose William Saldanha
-
Patent number: 7498414Abstract: The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal.Type: GrantFiled: March 4, 2003Date of Patent: March 3, 2009Assignee: ImClone Systems IncorporatedInventor: Zhenping Zhu
-
Publication number: 20090053241Abstract: The invention is directed to novel PDGFR?-specific antagonists. The antagonists include antibodies, which can be bispecific. The antibodies are used to reduce or inhibit tumor growth and or to treat an angiogenic disease. The invention also includes combinations of PDGFR?-specific antagonists with VEGFR antagonists for such treatments. The antagonists can further be administered in combination with other anti-angiogenic or anti-neoplastic drugs.Type: ApplicationFiled: April 17, 2008Publication date: February 26, 2009Applicant: ImClone Systems IncorporatedInventors: Zhenping Zhu, Juqun Shen
-
Publication number: 20090048301Abstract: The present invention relates to heterocyclic compounds that have anticancer activity, and pharmaceutical compositions that contain such compounds, methods of treating diseases and conditions in mammals using such compounds and composition and methods for their manufacture.Type: ApplicationFiled: July 9, 2004Publication date: February 19, 2009Applicant: IMCLONE SYSTEMS INCORPORATEDInventors: Xiaoling Chen, Hai-Ying He, Joel Kawakami, Alexander Kiselyov, Xiaohu Ouyang, Vatee Pattaropong, Evgueni Piatnitski, Maria Carolina Tuma, John Kincaid
-
Publication number: 20080118480Abstract: Method for modulating the migration of neural progenitor cells in a mammal by exposing the cells to a VEGFR-2 ligand and FGF-2. Methods of treating neurological disorders by exposing the mammal to a VEGFR-2 ligand in the presence of FGF-2 are also provided. A composition including a biocompatible matrix associated with FGF-2 is also provided.Type: ApplicationFiled: December 20, 2004Publication date: May 22, 2008Applicant: IMCLONE SYSTEMS INCORPORATEDInventors: Huanxiang Zhang, Laszlo Vutskits, Michael Pepper, Jozsef Zoltan Kiss
-
Patent number: 7060808Abstract: A nucleic acid is provided which encodes a humanized antibody or fragment thereof, which encodes a protein which binds to human EGF-receptor. Monoclonal antibody 225 is the complementary determining region (CDR) donor.Type: GrantFiled: June 7, 1996Date of Patent: June 13, 2006Assignee: ImClone Systems IncorporatedInventors: Neil I. Goldstein, Nicholas A. Giorgio, Steven Tarran Jones, Jose William Saldanha
-
Patent number: 6991794Abstract: Disclosed are the FRIL family of progenitor cell preservation factors and nucleic acids encoding the same. FRIL family members preserve progenitor cells both in vivo and ex vivo. FRIL family members find use as therapeutics for alleviating and/or reducing the hematopoietic progenitor cell-depleting activity of many cancer therapeutics. FRIL family members are also useful for isolating rare, primitive progenitor cells.Type: GrantFiled: December 30, 1999Date of Patent: January 31, 2006Assignees: ImClone Systems Incorporated, The Regents of the University of CaliforniaInventors: M. Gabriella Colucci, Maarten J. Chrispeels, Jeffrey G. Moore
-
Publication number: 20050181997Abstract: Disclosed is the FRIL family of progenitor cell preservation factors and nucleic acids encoding the same. FRIL family members preserve progenitor cells both in vivo and ex vivo. FRIL family members find use as therapeutics for alleviating and/or reducing the hematopoietic progenitor cell-depleting activity of many cancer therapeutics. FRIL family members are also useful for isolating rare, primitive progenitor cells.Type: ApplicationFiled: March 16, 2005Publication date: August 18, 2005Applicants: Regents of the University of California, ImClone Systems IncorporatedInventors: M. Colucci, Maarten Chrispeels, Jeffrey Moore
-
Publication number: 20050060779Abstract: The invention relates to an isolated nucleic acid molecule that encodes a protein that is effective to preserve progenitor cells, such as hematopoietic progenitor cells. The nucleic acid comprises a sequence defined by SEQ ID NO:1, a homolog thereof, or a fragment thereof. The encoded protein has an amino acid sequence that comprises a sequence defined by SEQ ID NO:2, a homolog thereof or a fragment thereof that contains an amino acid sequence TNNVLQVT. Methods of using the encoded protein for preserving progenitor cells in vitro, ex vivo, and in vivo are also described. The invention, therefore, include methods such as myeloablation therapies for cancer treatment wherein myeloid reconstitution is facilitated by means of the specified protein.Type: ApplicationFiled: August 30, 2004Publication date: March 17, 2005Applicants: ImClone Systems Incorporated, Regents of the University of CaliforniaInventors: M. Colucci, Maarten Chrispeels, Jeffrey Moore
-
Patent number: 6852533Abstract: The invention is directed to a purified population of mammalian endothelial, muscle, or neural stem cells. The invention further provides methods for isolating such populations of cells; methods for using such populations of cells for treating mammals; methods for making vectors for gene therapy; and methods for carrying out gene therapy with such vectors.Type: GrantFiled: January 25, 1999Date of Patent: February 8, 2005Assignees: Cornell Research Foundation, Inc., Sloan-Kettering Institute for Cancer Research, ImClone System IncorporatedInventors: Shahin Rafii, Larry Witte, Malcolm A. S. Moore
-
Patent number: 6852321Abstract: The invention relates to an isolated nucleic acid molecule that encodes a protein that is effective to preserve progenitor cells, such as hematopoietic progenitor cells. The nucleic acid comprises a sequence defined by SEQ ID NO:1, a homolog thereof, or a fragment thereof. The encoded protein has an amino acid sequence that comprises a sequence defined by SEQ ID NO:2, a homolog thereof or a fragment thereof that contains an amino acid sequence TNNVLQVT. Methods of using the encoded protein for preserving progenitor cells in vitro, ex vivo, and in vivo are also described. The invention, therefore, include methods such as myeloablation therapies for cancer treatment wherein myeloid reconstitution is facilitated by means of the specified protein.Type: GrantFiled: October 29, 2001Date of Patent: February 8, 2005Assignees: ImClone Systems Incorporated, Regents of the University of CaliforniaInventors: M. Gabriella Colucci, Maarten J. Chrispeels, Jeffrey G. Moore
-
Publication number: 20040229206Abstract: The invention relates to a protein material which is effective to preserve progenitor cells, such as hematopoietic progenitor cells. The protein has an amino acid sequence comprising AQSLSFSFTKFD (SEQ ID NO:1) and a molecular weight of about 12-20 kD, or has an amino acid sequence comprising VVAVEFD (SEQ ID NO:3) and a molecular weight of about 15-20 kD. Heterodimers of the protein are described, and multimers thereof. Methods of using the protein of the invention for preserving progenitor cells in vitro, ex vivo, and in vivo are also described. The invention, therefore, include methods such as myeloablation therapies for cancer treatment wherein myeloid reconstitution is facilitated by means of the specified protein.Type: ApplicationFiled: December 15, 2003Publication date: November 18, 2004Applicant: ImClone Systems incorporatedInventor: Jeffrey G. Moore
-
Patent number: 6811779Abstract: The invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation. In addition, the invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and a chemotherapeutic agent.Type: GrantFiled: March 2, 2001Date of Patent: November 2, 2004Assignee: ImClone Systems IncorporatedInventors: Patricia Rockwell, Neil I. Goldstein
-
Patent number: 6613565Abstract: Primitive hematopoietic stem cells are closely associated with discrete in vivo microenvironments. These “niches” are thought to provide the molecular signals that mediate stem cell differentiation and self renewal. We have dissected the fetal liver microenvironment into distinct cellular components by establishing an extensive panel of stromal cell lines. One particular cell line maintains repopulating stem cells for prolonged in vitro culture periods. A subtraction cloning strategy has yielded a cDNA which encodes a cell surface glycoprotein with a restricted pattern of expression among stromal cell lines. This molecule, previously identified as dlk/Pref-1, contains EGF-like repeats which are related to those in the Notch/Delta/Serrate family of proteins. We have investigated the potential role of this molecule in hematopoietic stem/progenitor cell regulation.Type: GrantFiled: December 8, 1998Date of Patent: September 2, 2003Assignees: ImClone Systems Incorporated, Trustees of Princeton UniversityInventors: Larry Witte, Bronislaw Pytowski, Kateri A. Moore, Ihor R. Lemischka
-
Patent number: 6410723Abstract: A substantially purified nucleic acid molecule comprising a VDUP1 promoter region, capable of directing expression of a polypeptide encoding sequence to which it is operably linked, whose expression is induced to maximal levels as a result of prolonged cell culture.Type: GrantFiled: July 24, 2000Date of Patent: June 25, 2002Assignee: Imclone Systems IncorporatedInventor: Dale Ludwig